At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 1, 2026 at 09:45 ET
Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU and SD, showing that retreatment leads to rapid and high rates of complete response, supporting the potential for intermittent, real-world treatment. The data reinforce the drug's durable efficacy and favorable safety profile, with 62% (ColdU) and 60% (SD) achieving complete response upon retreatment. A global Phase 3 trial is ongoing.
- Barzolvolimab retreatment achieved 62% complete response in ColdU and 60% in SD at Week 20 of the OLE, consistent with initial treatment efficacy.
- Among patients who achieved complete response initially, 82% (ColdU) and 86% (SD) achieved it again upon retreatment.
- Rapid improvement in urticaria control and symptom thresholds observed upon retreatment.
- Barzolvolimab targets mast cells via KIT receptor inhibition, a novel mechanism for chronic inducible urticarias.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access